



Targeted Protein Degradation: From Chemical Biology to Drug Discovery

Guest Editors:

Dr. Mikihiro Naito

Chief, Division of Molecular
Target and Gene Therapy
Products, National Institute of
Health Sciences, 3-25-26
Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-9501,
Japan

Dr. Yosuke Demizu

Chief, Division of Organic
Chemistry, National Institute of
Health Sciences, 3-25-26
Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-9501,
Japan

Deadline for manuscript
submissions:

closed (31 March 2020)

Message from the Guest Editors

Dear Colleagues,

Protein degradation induced by small molecules has been attracting great attention recently as a novel modality for drug development and as a novel method for basic research in chemical biology. This technology hijacks the cellular ubiquitin-proteasome system to induce protein degradation, as demonstrated by chimeric molecules (PROTACs, SNIPERs), small E3 modulators (thalidomides, sulfonamides), SERD (fulvestrant), etc.. Probably, this technology could be extended to the manipulation of other cellular events involving ubiquitin and, further, to other post translational modification systems in the future.

To explore the future possibilities of this novel technology, authors are invited to submit original and review articles on any aspect of the chemical compounds and methods capable of regulating protein degradation and the cellular ubiquitin system, including, but not limited to, protein degraders, protein degradation systems, modifiers of the ubiquitin system, etc. The collection of manuscripts will be published as a Special Issue of the journal *Pharmaceuticals*.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com